Science1 publisher2 min readPublished
Blood exosomes from seven shingles pain patients carried extra neuron-growth suppressors
Fewer than half of people with post-herpetic neuralgia get meaningful relief from current drugs, so a team compared blood exosomes from seven patients and seven controls and found proteins that hold nerve growth back.
The Scientist · Science desk
What happened
- Shingles pain that outlasts three months is called post-herpetic neuralgia, and because its mechanisms are unknown, treatment aims at symptoms and gives fewer than half of patients meaningful relief.
- A team writing in Annals of Neurology isolated exosomes from the blood of seven patients with the condition and seven without it, then compared the protein cargo of each group.
- Exosomes from the patients with post-herpetic neuralgia held significantly higher concentrations of proteins known to suppress the growth of neurons.
- The team then exposed human sensory neurons in a petri dish to exosomes from both groups and watched them with live-cell imaging, the step meant to test whether the particles act on neurons.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- constraint A fourteen-person comparison can establish that two groups differ. It cannot establish that the difference caused the pain, so the target hypothesis rests entirely on the dish work and whatever follows it.
- decision Anyone designing the next post-herpetic neuralgia trial has to choose between pressing harder on viral replication and testing a blood-borne messenger, and the antiviral record argues against the first.
- cost For the majority of patients who get no meaningful relief, the missing mechanism means months or years of pain.
- capability Because exosomes travel in blood, a driver identified this way would be measurable from a vein, and a test for who is at risk could plausibly arrive before any drug does.
Seven against seven is fourteen people. A proteomic comparison that size can find a large difference in average protein concentration between two groups. It cannot tell you which direction the causation runs. Long-standing pain changes sleep, activity and medication, and all of those change what cells package into the particles they release. The report that exosomes from post-herpetic neuralgia patients carry more neuron-growth suppressors fits the idea that the particles are holding nerve fibers back, and it fits the reverse just as well.
The dish experiment is designed to break that tie. Sensory neurons in a petri dish have no pain history and no drug exposure of their own, so if exosomes from patients change how those neurons grow, the direction is settled inside the well. The Conversation account describes the design, including live-cell imaging, but does not report the result.
The clinical clue that makes a non-viral suspect worth chasing predates this paper. Antiviral treatment that shuts down viral replication does not reliably prevent or reduce post-herpetic neuralgia. The biopsies are stranger still: in painful skin that looks normal, sensory nerve fibers are reduced, and having fewer fibers goes with more pain rather than less. What stops those fibers from repairing after the infection clears is unknown.
The varicella zoster virus has infected over 90% of the world's population, and it reactivates as shingles in roughly a third. Of those cases, 10% to 18% progress to post-herpetic neuralgia months after the rash has cleared. A third of 10% is 3.3%. A third of 18% is 6.0%. On those figures, somewhere between three and six people in a hundred are candidates for this condition at some point in life. That range does not describe severity or duration. The same account reports that in some patients the pain persists for years or for the rest of their lives, and it reports a significant decline in quality of life, suicidal thoughts and emotional distress.
Removing or neutralising the suppressive cargo would have to restore outgrowth in human neurons, then change pain behaviour in an animal, then survive a trial in people whose pain has already lasted more than three months. The same laboratory has previously reported that exosomes in the blood during an active shingles rash can raise stroke risk and inflammation.
Prevention does not empty the reservoir. The virus goes dormant in pain-sensing neurons after the first infection. The varicella vaccine uses a live weakened strain, so children vaccinated in the United States since 1995 still carry dormant virus in those cells. No one has explained why shingles rates are rising worldwide.
What to watch
- The live-cell imaging result in the Annals of Neurology paper: whether patient exosomes reduced neurite outgrowth, and by how much against control exosomes.
- Replication in a cohort large enough to match patients and controls for age, given that post-herpetic neuralgia risk rises steeply with age.
- Whether depleting or blocking the specific suppressor proteins restores nerve regrowth in a model.